IFP Advisors’s INmune Bio INMB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $386 | Sell |
198
-10
| -5% | -$21 | ﹤0.01% | 4736 |
|
|
2026
Q2 | $339 | Sell |
208
-2
| -1% | -$3 | ﹤0.01% | 4758 |
|
|
2026
Q1 | $237 | Buy |
210
+15
| +8% | +$21 | ﹤0.01% | 4583 |
|
|
2025
Q4 | $304 | Sell |
195
-5
| -3% | -$9 | ﹤0.01% | 4402 |
|
|
2025
Q3 | $414 | Buy |
200
+16
| +9% | +$37 | ﹤0.01% | 4237 |
|
|
2025
Q2 | $425 | Hold |
184
| – | – | ﹤0.01% | 4480 |
|
|
2025
Q1 | $1.44K | Hold |
184
| – | – | ﹤0.01% | 3248 |
|
|
2024
Q4 | $859 | Hold |
184
| – | – | ﹤0.01% | 3310 |
|
|
2024
Q3 | $992 | Hold |
184
| – | – | ﹤0.01% | 3078 |
|
|
2024
Q2 | $1.62K | Hold |
184
| – | – | ﹤0.01% | 2865 |
|
|
2024
Q1 | $2.16K | Hold |
184
| – | – | ﹤0.01% | 2674 |
|
|
2023
Q4 | $2.07K | Hold |
184
| – | – | ﹤0.01% | 2672 |
|
|
2023
Q3 | $1.25K | Hold |
184
| – | – | ﹤0.01% | 2952 |
|
|
2023
Q2 | $1.67K | Hold |
184
| – | – | ﹤0.01% | 2932 |
|
|
2023
Q1 | $1.47K | Sell |
184
-184
| -50% | -$1.48K | ﹤0.01% | 2986 |
|
|
2022
Q4 | $2K | Buy |
368
+184
| +100% | +$1.31K | ﹤0.01% | 4173 |
|
|
2022
Q3 | $1K | Hold |
184
| – | – | ﹤0.01% | 4585 |
|
|
2022
Q2 | $1K | Hold |
184
| – | – | ﹤0.01% | 4358 |
|
|
2022
Q1 | $1K | Hold |
184
| – | – | ﹤0.01% | 4357 |
|
|
2021
Q4 | $2K | Sell |
184
-100
| -35% | -$1.48K | ﹤0.01% | 2799 |
|
|
2021
Q3 | $6K | Buy |
284
+100
| +54% | +$1.93K | ﹤0.01% | 2491 |
|
|
2021
Q2 | $3K | Hold |
184
| – | – | ﹤0.01% | 2637 |
|
|
2021
Q1 | $2K | Buy |
+184
| New | +$3.31K | ﹤0.01% | 2679 |
|
Other funds holding INMB
BFA
EP
IFP Advisors's INMB Position: Q3 2026 in Review
IFP Advisors reduced its INmune Bio (INMB) stake by 4.8% in Q3 2026, selling an estimated $21 and leaving 198 shares worth $386. The position accounts for ﹤0.01% of the portfolio, ranked #4736.
IFP Advisors first reported a position in INMB in Q1 2021 and has held it in 23 quarters since. The position peaked at $6K in Q3 2021. 5 funds tracked by Wall St. Rank hold INMB as of Q3 2026.
- IFP Advisors held 198 shares of INmune Bio worth $386 as of Q3 2026.
- IFP Advisors sold 10 INmune Bio shares in Q3 2026, an estimated $21.
- INmune Bio made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #4736 holding.
- IFP Advisors first reported a position in INmune Bio in Q1 2021 and has held it in 23 quarters since.
- IFP Advisors's INmune Bio position peaked at $6K in Q3 2021.
- 5 funds tracked by Wall St. Rank held INmune Bio as of Q3 2026.
Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.